A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
<h4>Background</h4>The Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in registry-based studies.<h4>Mat...
Guardado en:
Autores principales: | Giuseppe Fallara, Rolf Gedeborg, Anna Bill-Axelson, Hans Garmo, Pär Stattin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a6d8ad71fb2473aadf774cc8d7856c0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
por: Rolf Gedeborg, et al.
Publicado: (2021) -
Mortality following hip fracture in men with prostate cancer.
por: Mieke Van Hemelrijck, et al.
Publicado: (2013) -
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
por: Emma Hörnberg, et al.
Publicado: (2011) -
Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: E. Lin, et al.
Publicado: (2021) -
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Mamta Parikh, et al.
Publicado: (2021)